Evidence map›Paper›PMID 26924353›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2016

Polymeric materials for embolic and chemoembolic applications.

Azadeh Poursaid, Mark Martin Jensen, Eugene Huo, Hamidreza Ghandehari

Abstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Embolic Agents: Particles.Seminars in interventional radiology · 2023
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Hydrogel systems for targeted cancer therapy.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Azadeh PoursaidDepartment of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA; Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA.
Mark Martin JensenDepartment of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA; Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA.
Eugene HuoVeterans Affairs Hospital, Salt Lake City, UT 84108, USA.
Hamidreza GhandehariDepartment of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA; Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: hamid.ghandehari@pharm.utah.edu.
University of Utah · USVeterans Health Administration · US

Funding

Engineering Polymers For Gene Therapy of Head CancerR01CA107621 · NCI · UNIVERSITY OF UTAH · PI GHANDEHARI, HAMID · 2005 to 2014
$2.5M
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic CarcinomaR42CA168123 · NCI · THERATARGET · PI CHENEY, DARWIN LEROY, GHANDEHARI, HAMID · 2016 to 2019
$1.5M
In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic CarcinomaR41CA168123 · NCI · THERATARGET · PI GHANDEHARI, HAMID · 2012 to 2012
$100k
Recombinant Polymers for Transarterial Chemoembolization of Liver CancerF30CA176922 · NCI · UNIVERSITY OF UTAH · PI POURSAID, AZADEH · 2013 to 2016
$99k
NCI NIH HHS F30 CA176922NCI NIH HHS R01 CA107621NCI NIH HHS R41 CA168123NCI NIH HHS R42 CA168123
6 · The paper itself

Abstract

Percutaneous transcatheter embolization procedures involve the selective occlusion of blood vessels. Occlusive agents, referred to as embolics, vary in material characteristics including chemical composition, mechanical properties, and the ability to concurrently deliver drugs. Commercially available polymeric embolics range from gelatin foam to synthetic polymers such as poly(vinyl alcohol). Current systems under investigation include tunable, bioresorbable microspheres composed of chitosan or poly(ethylene glycol) derivatives, in situ gelling liquid embolics with improved safety profiles, and radiopaque embolics that are trackable in vivo. This article reviews commercially available materials used for embolization as well as polymeric materials that are under investigation.

Indexed as

Antineoplastic AgentsChemoembolization, TherapeuticChitosanDrug CarriersGelatin Sponge, AbsorbableHumansNeovascularization, PathologicPolyethylene GlycolsPolymersVascular MalformationsAntineoplastic AgentsChitosanDrug CarriersPolyethylene GlycolsPolymersArteriovenous malformationsDrug eluting beadsEmbolicsHepatocellular carcinomaPolymersUterine fibroids

Identifiers

PMID26924353
PMCPMC5001944
OpenAlexW2276728785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.